Okulista badający pacjentkę przy lampie szczelinowej

Selenium and Mild Graves' Orbitopathy — What a Randomized Trial Showed

Q: What's the difference between Graves' disease and Hashimoto's?

These are two opposite autoimmune thyroid diseases. In Graves' disease, antibodies stimulate the thyroid to overproduce hormones (hyperthyroidism), while in Hashimoto's they destroy the thyroid, leading to hormone deficiency (hypothyroidism). The symptoms are largely opposite — accelerated metabolism and weight loss in Graves' disease versus slowing down and weight gain in Hashimoto's.

Q: What is Graves' orbitopathy, and does it affect every patient with this disease?

Graves' orbitopathy is an autoimmune inflammatory condition of the orbital tissues, causing proptosis, eyelid swelling, and double vision, among other things. It doesn't occur in every patient with Graves' disease — it affects only some of them, with varying severity, from mild to severe, vision-threatening forms.

Q: What selenium dose was used in the EUGOGO study?

100 mcg of selenium twice daily (200 mcg total per day) for 6 months. That dose falls within the range considered safe for most adults, but decisions about using it and for how long are worth discussing with a physician, since long-term intake above the recommended upper limits for selenium carries a risk of selenosis.

Q: Will selenium also help with moderate or severe Graves' orbitopathy?

The EUGOGO study doesn't answer that question — it enrolled only patients with the mild form of the disease. Moderate and severe orbitopathy require other, more aggressive treatment methods (including intravenous glucocorticoids, orbital radiotherapy, and surgery) carried out at a specialized center.

Q: Why did pentoxifylline, tested in the same study, fail to work?

Despite a reasonable biological rationale (potential anti-inflammatory action), pentoxifylline showed no significant advantage over placebo on any of the evaluated orbitopathy parameters, and additionally caused gastrointestinal complaints more often. This shows that a biological mechanism alone doesn't guarantee real clinical effectiveness — hence the value of placebo-controlled trials.

Q: Does selenium treat the hyperthyroidism in Graves' disease?

No. The EUGOGO study assessed only selenium's effect on the course of orbitopathy — the eye complication — not on thyroid function itself. Treating the hyperthyroidism in Graves' disease (antithyroid drugs, radioactive iodine, or surgery) is a separate clinical decision made by an endocrinologist, independent of any selenium supplementation.

Q: Does smoking matter for Graves' orbitopathy?

Yes — smoking is one of the most strongly documented factors increasing the risk of developing and worsening Graves' orbitopathy. Quitting smoking is considered one of the most important non-pharmacological actions a patient with this disease can take, regardless of any drug treatment or supplementation.

Q: Do people with Graves' orbitopathy actually have lower selenium levels?

An Australian case-control study of 198 patients with Graves' disease found that serum selenium was significantly lower in those with orbitopathy than in those without it, and dropped further with increasing disease severity. This association remained significant after adjusting for smoking, age, and prior thyroid treatment, supporting selenium status as an independent risk factor — alongside, not instead of, the randomized trial evidence that supplementation helps.

Graves' disease is hyperthyroidism — the opposite of the far more commonly discussed Hashimoto's. In some patients it's accompanied by Graves' orbitopathy, an inflammatory eye disease that can cause more suffering than the hyperthyroidism itself. A large, multicenter randomized trial published in the New England Journal of Medicine tested whether selenium helps in the mild form of this eye disease — and simultaneously showed that another tested drug, pentoxifylline, failed.

PZdr Piotr ZielińskiAugust 27, 202613 min read

Table of contents

TL;DR — key takeaways

→Graves' disease is not Hashimoto's — two opposite sides of the thyroid
→What Graves' orbitopathy is
→What the EUGOGO study showed
→Why selenium specifically — low selenium status as a risk factor
→Pentoxifylline failed — and that's also an important result
→What this study doesn't show — limitations
→Selenium for orbitopathy — myth or fact
→What's worth doing in practice
→Selenium and Graves' orbitopathy in brief
→Our editorial recommendation

Graves' disease is not Hashimoto's — two opposite sides of the thyroid

Hashimoto's disease, which we've already covered on this blog in connection with ashwagandha and thyroid supplementation, is autoimmune hypothyroidism — the immune system gradually destroys the gland, hormone production falls, and the patient slows down: gaining weight, feeling cold, tired, and sleepy. Graves' disease is its mirror image. It's also an autoimmune disease, but the antibodies don't destroy the thyroid — instead they overstimulate it, binding to the TSH receptor and forcing the gland to produce excess hormones. The effect is the opposite of Hashimoto's: rapid heart rate, weight loss despite a good appetite, excessive sweating, hand tremor, anxiety, and insomnia.

This distinction matters in practice, because the two diseases are often confused in casual conversations about "thyroid problems," yet they're treated in completely different ways — hyperthyroidism in Graves' disease requires antithyroid drugs, radioactive iodine therapy, or surgery, while hypothyroidism in Hashimoto's is treated with thyroid hormone replacement. This article is not about treating the hyperthyroidism itself in Graves' disease — that's a separate topic requiring an endocrinologist's decision. We focus on a specific, well-studied complication affecting some patients with this disease: Graves' orbitopathy.

What Graves' orbitopathy is

Graves' orbitopathy (also called Graves' ophthalmopathy or thyroid eye disease) is an autoimmune inflammatory condition of the tissues of the eye socket — the muscles that move the eyeball, and the fat and connective tissue behind the eye. The same antibodies that overstimulate the thyroid in Graves' disease also attack receptors present in orbital tissues, causing swelling, inflammatory infiltration, and, over the longer term, fibrosis. Clinically this presents as proptosis (bulging of the eyeballs), eyelid swelling, conjunctival redness, a gritty feeling under the eyelids, double vision, and in more severe cases pain and threat to vision from pressure on the optic nerve.

Not every Graves' patient has orbitopathy

Orbitopathy develops in some, not all, patients with Graves' disease, and its severity varies — from mild, cosmetic changes to severe, vision-threatening forms. Smoking is one of the strongest, well-documented risk factors for developing and worsening orbitopathy, making smoking cessation one of the most important non-pharmacological steps for patients with this diagnosis.

It was in the context of this mild form of the eye disease that the European research group EUGOGO (European Group on Graves' Orbitopathy) conducted a randomized clinical trial testing whether a simple, cheap, and widely available trace element — selenium — could actually help.

What the EUGOGO study showed

Selenium and the course of mild Graves' orbitopathy

Strong evidence

Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, et al. (European Group on Graves' Orbitopathy) · New England Journal of Medicine · 2011

This randomized, double-blind, placebo-controlled trial enrolled 159 patients with mild Graves' orbitopathy. Participants were assigned to one of three groups: selenium at 100 mcg twice daily, pentoxifylline 600 mg twice daily, or placebo, for 6 months, with an additional 6-month follow-up off treatment. The selenium group showed a statistically significant improvement in quality of life (p<0.001), less severe eye involvement (p=0.01), and markedly slower disease progression compared with placebo (p=0.01). Two patients in the placebo group and one in the pentoxifylline group required immunosuppressive treatment due to disease progression — no such case occurred in the selenium group. No adverse effects related to selenium use were observed. An exploratory assessment at 12 months (i.e., six months after supplementation ended) confirmed that the benefits seen at month 6 were maintained.

View study

Several features of this study make it particularly credible: it's not a small, single-center report, but a multicenter trial conducted in parallel across several European reference centers specializing in Graves' orbitopathy, with double blinding (neither patients nor evaluating physicians knew who received which preparation) and a placebo control group rather than simply no treatment. The effect also persisted after supplementation stopped, suggesting a real influence on the disease course rather than just temporary symptom relief while taking the preparation.

Why selenium specifically — low selenium status as a risk factor

The EUGOGO trial tested selenium as a treatment, but a separate line of research asked a different, complementary question: do people who develop Graves' orbitopathy actually tend to have lower selenium status to begin with? A case-control study conducted in Australia set out to answer exactly that.

Serum selenium status in Graves' disease with and without orbitopathy: a case-control study

Moderate evidence

Khong JJ, Goldstein RF, Sanders KM, Schneider H, Pope J, Burdon KP, Craig JE, Ebeling PR · Clinical Endocrinology · 2014

A prospective case-control study of 198 patients with Graves' disease (101 with orbitopathy, 97 without), conducted at endocrine and ophthalmology clinics in Australia between 2009 and 2012. Mean serum selenium was significantly lower in patients with orbitopathy than in those without it (1.10 ± 0.18 µmol/L vs 1.19 ± 0.20 µmol/L; p=0.001), and selenium levels decreased further with increasing orbitopathy severity (1.09 µmol/L in sight-threatening disease; p=0.003 across groups). The association with lower selenium remained significant after adjusting for age, smoking, thyroidectomy, radioactive iodine treatment, and place of residence, leading the authors to conclude that relative selenium deficiency may be an independent risk factor for orbitopathy in Graves' disease.

View study

Two separate pieces of evidence pointing the same direction

Moderate evidence

This case-control study doesn't prove cause and effect on its own — it shows an association, not an interventional effect — but it strengthens the overall picture when read alongside the EUGOGO trial. One study shows that people with (more severe) orbitopathy tend to have lower selenium status; the other shows that correcting selenium status with supplementation measurably improves the mild form of the disease. Together they make a more coherent case than either finding would on its own, though neither establishes that low selenium is the primary cause of orbitopathy in every patient.

Pentoxifylline failed — and that's also an important result

The third arm of this study — pentoxifylline, a drug used among other things for peripheral circulatory disorders, tested here for its potential anti-inflammatory action — showed no significant advantage over placebo on any of the evaluated orbitopathy parameters. Moreover, patients taking pentoxifylline reported gastrointestinal complaints more often than in the other two groups, and one of them required escalation to immunosuppression despite treatment.

Why this contrast matters

Strong evidence

This is a good illustration of why placebo-controlled trials with more than one experimental arm are done in the first place: merely "trying something" isn't automatically better than doing nothing, and confidence in a drug's effect based on a biological mechanism (here: pentoxifylline's potential anti-inflammatory action) doesn't always translate into a real clinical effect. This particular study's rigor — three arms, blinding, shared uniform evaluation criteria — made it possible to clearly distinguish an intervention that actually worked (selenium) from one that, despite a reasonable biological rationale, brought no benefit while also generating side effects (pentoxifylline).

Check your profile

Not sure which supplements actually make sense for you?

Answer a few short questions about your lifestyle, diet, sleep, and goals. VitMode will build your profile and show supplements worth considering — with reasoning and evidence strength.

Takes about 2 minutesBased on scientific evidence

Find supplements for me

Recommendations take your answers and the strength of the scientific evidence into account. A supplement's popularity has no bearing on whether it gets recommended.

What this study doesn't show — limitations

Important caveats before drawing conclusions

The EUGOGO study concerned only mild Graves' orbitopathy. It says nothing about whether selenium helps in moderate or severe orbitopathy, where the standard of care is entirely different — high-dose intravenous glucocorticoids, orbital radiotherapy, or surgical treatment, implemented only under specialist care. The study also didn't assess selenium's effect on the hyperthyroidism itself in Graves' disease — that's a completely separate clinical problem requiring its own independent treatment (antithyroid drugs, radioactive iodine, or surgery), which selenium in no way replaces. It's also worth remembering that selenium is toxic in excess — the dose used in the study (200 mcg per day total) falls within the range considered safe for most adults, but long-term supplementation above the recommended upper limits can lead to selenosis, so decisions about supplementation and its duration are always worth discussing with a treating physician rather than taking selenium indefinitely on one's own.

Selenium for orbitopathy — myth or fact

Myth

Selenium is a natural supplement, so it can be used safely and without restriction for any form of Graves' orbitopathy and for the hyperthyroidism itself.

Fact

The evidence from the randomized trial applies specifically to the mild form of orbitopathy, a specific dose (100 mcg twice daily), and a limited duration of use (6 months). There is no evidence that selenium treats hyperthyroidism in Graves' disease, nor that it helps in moderate or severe forms of the eye disease — those require separate, specialist treatment. "Natural" also doesn't mean "without an upper safety limit" — chronic use of selenium at doses far exceeding those in the study carries a risk of selenosis.

What's worth doing in practice

Practical takeaways for people with Graves' disease and eye symptoms

New eye symptoms (proptosis, eyelid swelling, double vision, pain, a gritty feeling under the eyelids) in someone diagnosed with Graves' disease require an ophthalmology and endocrinology consultation, not self-treatment with home remedies
The decision on possible selenium supplementation, its dose, and duration is best made together with a physician, taking into account the severity of orbitopathy and the patient's current iodine-selenium status
Quitting smoking is one of the best-documented, non-pharmacological actions that reduces the risk of developing and worsening Graves' orbitopathy
Treating the hyperthyroidism itself in Graves' disease (antithyroid drugs, radioactive iodine, surgery) is a separate clinical decision, independent of any selenium supplementation
Moderate and severe orbitopathy require treatment at a specialized reference center — the mild form studied here is not the same clinical condition as the vision-threatening forms

Selenium and Graves' orbitopathy in brief

Question	Short answer
Does selenium help with Graves' orbitopathy?	Yes, but only in the mild form — improved quality of life (p<0.001), less eye involvement (p=0.01), slower progression (p=0.01)
Did pentoxifylline, tested in the same study, work?	No — no significant advantage over placebo, and more frequent gastrointestinal complaints
Did selenium's effect persist after supplementation stopped?	Yes — the 12-month assessment (6 months after treatment ended) confirmed the 6-month results
Does selenium treat the hyperthyroidism itself in Graves' disease?	No — that's a separate problem requiring its own treatment (antithyroid drugs, radioactive iodine, surgery)
Do the results apply to moderate and severe orbitopathy too?	No — the study enrolled only patients with the mild form of the disease

Key takeaways from the EUGOGO study (NEJM, 2011)

Our editorial recommendation

This is a rare example of a study that, in a single experiment, provides both strong evidence "for" (selenium) and equally strong evidence "against" (pentoxifylline) — with both answers coming from the same rigorous methodology, the same patient population, and the same team of researchers. That internal consistency makes the results unusually credible compared with separate, independent studies that are harder to compare directly.

Selenium in this study is not a miracle cure for Graves' disease — it's a specific, well-studied intervention for a specific, mild form of one of its complications. That precision, rather than the generic slogan "selenium supports the thyroid," is what makes this result worth attention.

Dr. Piotr Zielinski, VitMode editorial team

Frequently asked questions